▪ Further investigate patients’ perspective|
▪ Organize additional training on pharmacogenomics for physicians.
▪ Use desired technical specifications as a guideline for development of a NGS panel.|
▪ Develop user-friendly FFPE-capable NGS panels.
▪ Further investigate willingness-to-pay|
▪ Set cost-effectiveness as a high priority to facilitate reimbursement.
|Clinical utility and evidence generation||▪ Advocate novel evidence generation designs.|
|Market access||▪ Enter the market rapidly to maximize window of opportunity|